Union College, Schenectady, NY, 2000-2004, BS (Psychology)
University of Washington, Seattle, WA, 2006-2008, MHA (Health Services Administration)
University of Washington, Seattle, WA, 2008-2012, PhD (Pharmaceutical Outcomes Research & Policy)
Application of comparative effectiveness research and patient-centered outcomes research methods to inform translation of lung, breast, and prostate cancer diagnostics and therapeutics, including: observational study design, decision modeling, randomized controlled trial design, systematic review and meta-analysis.
My current research focuses on evaluating comparative effectiveness and patient perspectives in lung cancer screening. Recent evidence from the National Lung Screening Trial demonstrated that low-dose computed tomography (LDCT) lung cancer screening resulted in a 20% reduction in lung cancer mortality vs. x-ray screening. Based largely on this finding, guidelines from the U.S. Preventive Services Task Force (USPSTF) and National Comprehensive Cancer Network (NCCN) were updated to recommend annual LDCT lung cancer screening for millions of heavy smokers in the United States. LDCT lung cancer screening is now a covered preventative service in the vast majority of U.S. health insurance plans, and healthcare systems across the U.S. are developing programs to offer screening to eligible plan members. This type of large-scale change in medical practice will involve many complex decisions between alterative strategies and medical technologies. The overall objective of my research is to measure and interpret the outcomes of these alternative strategies and medical technologies using a range of comparative effectiveness research and patient-centered outcomes research methods.